Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Liposomal combination of cytarabine and daunorubicin

EU orphan designation number: EU/3/11/942   
Active ingredient: Liposomal combination of cytarabine and daunorubicin
Indication: Treatment of acute myeloid leukaemia
Sponsor: Celator (UK) Ltd
c/o Blick Rothenberg LLP, Chartered Accountants, 16 Great Queen Street, Covent Garden, London WC2B 5AH, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
13/01/2012 Orphan designation EMA/OD/070/11 (2012)128 of 11/01/2012
12/03/2014 Change of name and/or address of sponsor